A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects

Molecular Endocrinology

Volumn 17, Issue 5, 2003, Pages 860-869

  Coghlan, Michael J ^a,d   Jacobson, Peer B ^a   Lane, Ben ^a   Nakane, Masaki ^a   Lin, Chun Wei ^a   Elmore, Steven W ^a   Kym, Philip R ^a   Luly, Jay R ^a,e   Carter, George W ^a   Turner, Russell ^c   Tyree, Curtis M ^b   Hu, Junlian ^b   Elgort, Marc ^b   Rosen, Jon ^b   Miner, Jeffrey N ^b  

^a ABBOTT LABORATORIES   (United States)

^b LIGAND PHARMACEUTICALS INC   (United States)

^c MAYO CLINIC   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Oxford Bioscience Partners   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AL 438; ANTIINFLAMMATORY AGENT; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1; PREDNISOLONE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; GENE ACTIVATION; GENE CONTROL; GENE REPRESSION; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; MALE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; BENZOPYRANS; BONE AND BONES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; EDEMA; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MALE; NUCLEAR RECEPTOR COACTIVATOR 2; PREDNISOLONE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; TIBIA; TRANSCRIPTION FACTORS;

ANIMALIA;

EID: 12444276298     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2002-0355     Document Type: Article

References (44)

1. Stanbury RM, Graham EM 1998 Systemic corticosteroid therapy - side effects and their management. Br J Ophthalmol 82:704-708
2. Barnes PJ 1998 Anti-inflammatory actions of glucocorticoids: molecular mechanisms [editorial]. Clin Sci (Colch) 94:557-572
3. Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841-850
4. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889-895
5. Miner JN, Yamamoto KR 1991 Regulatory crosstalk at composite response elements. Trends Biochem Sci 16:423-426
6. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272
7. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, Herrlich P 1990 Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone, Cell 62:1189-1204
8. van der Burg B, Liden J, Okret S, Delaunay F, Wissink S, van der Saag PT, Gustafsson J-A 1997 Nuclear factor-κB repression in anti-inflammation and immunosuppression by glucocorticoids. Trends Endocrinol Metab 8:152-157
9. Akira S, Kishimoto T 1997 NF-IL6 and NF-κB in cytokine gene regulation. Adv Immunol 65:1-46
10. Heck S 1998 Transcriptional repression as a molecular basis of the anti-inflammatory action of glucocorticoids. Karlsruhe: Wiss. Ber. Forschungszent University; pp. 1-110
11. Reichardt HM, Kaestner KH, Wessely O, Gass, P, Schmid W, Schutz G 1998 Analysis of glucocorticoid signalling by gene targeting. J Steroid Biochem Mol Biol 65:111-115
12. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 11:1245-1255
13. Belvisi MG, Wicks SL, Battram CH, Bottoms SE, Redford JE, Woodman P, Brown TJ, Webber SE, Foster ML 2001 Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J Immunol 166:1975-1982
14. Jenkins BD, Pullen CB, Darimont BD 2001 Novel glucocorticoid receptor coactivator effector mechanisms. Trends Endocrinol Metab 12:122-126
15. Nissen RM, Yamamoto KR 2000 The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 14:2314-2329
16. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, Rudolph D, Schutz G, Yoon C, Puigserver P, Spiegelman B, Montminy M 2001 CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413:179-183
17. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM 2001 Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131-138
18. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952
19. Rogatsky I, Zarember KA, Yamamoto KR 2001 Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 20:6071-6083
20. Elenkov IJ, Chrousos GP 2002 Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 966:290-303
21. Scott DK, Stromstedt PE, Wang JC, Granner DK 1998 Further characterization of the glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. The role of the glucocorticoid receptor-binding sites. Mol Endocrinol 12:482-491
22. Max SR 1990 Glucocorticoid-mediated induction of glutamine synthetase in skeletal muscle. Med Sci Sports Exerc 22:325-330
23. D'Haese J, Rutschmann M, Dahlmann B, Hinssen H 1987 Activity of a gelsolin-like actin modulator in rat skeletal muscle under protein catabolic conditions. Biochem J 248:397-402
24. Meyer T, Gustafsson JA, Carlstedt-Duke J 1997 Glucocorticoid-dependent transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. DNA Cell Biol 16:919-927
25. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389
26. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y 2001 Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16:479-482
27. Zhi L, Tegley CM, Edwards JP, West SJ, Marschke KB, Gottardis MM, Mais DE, Jones TK 1998 5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal progesterone receptor modulators. Bioorg Med Chem Lett 8:3365-3370
28. Elmore SW, Coghlan MJ, Anderson DD, Pratt JK, Green BE, Wang AX, Stashko MA, Lin CW, Tyree CM, Miner JN, Jacobson PB, Wilcox DM, Lane BC 2001 Nonsteroidal selective glucocorticoid modulators: the effect of C-5 alkyl substitution on the transcriptional activation/repression profile of 2,5-dihydro-10-methoxy-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines. J Med Chem 44:4481-4491
29. Shalhoub V, Aslam F, Breen E, van Wijnen A, Bortell R, Stein GS, Stein JL, Lian JB 1998 Multiple levels of steroid hormone-dependent control of osteocalcin during osteoblast differentiation: glucocorticoid regulation of basal and vitamin D stimulated gene expression. J Cell Biochem 69:154-168
30. Guido EC, Delorme EO, Clemm DL, Stein RB, Rosen J, Miner JN 1996 Determinants of promoter-specific activity by glucocorticoid receptor. Mol Endocrinol 10:1178-1190
31. Crilly R, Cawood M, Marshall DH, Nordin BE 1978 Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women. J R Soc Med 71:733-736
32. Walz DT, Di Martino MJ, Griffin CL, Misher A 1970 Investigation of the carrageenin-induced rat paw edema assay and correlation between anti-inflammatory activity and gastric hemorrhage production in the rat. Arch Int Pharmacodyn Ther 185:337-3 histopathology in the adjuvant arthritic rat. Arthritis Rheum 42:2060-2073
33. Jacobson PB, Morgan SJ, Wilcox DM, Nguyen P, Ratajczak CA, Carlson RP, Harris RR, Nuss M 1999 A new spin on an old model: in vivo evaluation of disease progression by magnetic resonance imaging with respect to standard inflammatory parameters and histopathology in the adjuvant arthritic rat. Arthritis Rheum 42:2060-2073
34. West KM, Johnson PC, Kyriakapoulos AA, Bahr WJ, Bloedow CE 1960 The physiologic effects of dexamethasone. Arthritis Rheum 3:129-139
35. Corry DB, Tuck ML 2001 Selective aspects of the insulin resistance syndrome. Curr Opin Nephrol Hypertens 10:507-514
36. Turner RT, Hannon KS, Demers LM, Buchanan J, Bell NH 1989 Differential effects of gonadal function on bone histomorphometry in male and female rats. J Bone Miner Res 4:557-563
37. Summers MDS, GE 1987 A manual of methods for baculovirus vectors and insect cell culture procedures. Tex Agric Exp Stn [Bull] 155
38. Wecksler WR, Norman AW 1979 An hydroxylapatite batch assay for the quantitation of 1α,25-dihydroxyvitamin D3-receptor complexes. Anal Biochem 92:314-323
39. DeBlasi A, O'Reilly K, Motulsky HJ 1989 Calculating receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10:227-229
40. Graham FL, van der Eb AJ 1973 A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467
41. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW 1992 The mechanism of RU486 antagonism is dependent on the conformation of the carboxyterminal tail of the human progesterone receptor. Cell 69:703-713
42. Knutti D, Kralli A 2001 PGC-1, a versatile coactivator. Trends Endocrinol Metab 12:360-365
43. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ 1994 Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800
44. Hollenberg SM, Giguere V, Segui P, Evans RM 1987 Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. Cell 49:39-46